The amyloid hypothesis of Alzheimer's disease at 25 years
Open accessThe DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Despite continuing debate about the amyloid β-protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease (AD). Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients' brains can decrease synapse number, inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau-positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid-PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oxidative stress, mitochondrial dysfunction, astrocytic and microglial activation, membrane perturbation, and loss of ionic homeostasis are, at the cellular level, some of the events downstream the Aβ1-42 aggregation and accumulation (Selkoe and Hardy, 2016).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Selkoe and Hardy, 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Synaptic dysfunction and synapse loss are key hallmarks of AD, present in the early stages of the disease before clinical symptoms appear [79,86,156].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the evidence from a failure of reversal of cognitive declines in amyloid-targeting drug trials supports this assumption; for example, patients with AD in whose brains Aβ plaques were virtually cleared by anti-amyloid immunotherapy did not show cognitive benefit [62].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early-stage AD is characterized primarily by the accumulation of Aβ plaques and subtle synaptic dysfunction, whereas late-stage AD involves extensive neurodegeneration, widespread neuroinflammation, and pronounced BBB disruption [157, 158].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [157]
Experimental — accuracy not yet measured
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“An elegant histopathological staging system created by Braak and Braak (1991) is now widely used to establish the severity of AD neuropathology.”
MethodThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“Cell biology of new AD risk genes Although the importance of ApoE4 as the major risk factor for AD was discovered in 1993 (Corder et al, 1993), it is only since the advent of genomewide association studies and, more recently, exome and genome sequencing that other risk loci for late-onset disease…”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“The amyloid (or Ab) hypothesis (Beyreuther & Masters, 1991; Hardy & Allsop, 1991; Selkoe, 1991; Hardy & Higgins, 1992) has become the dominant model of AD pathogenesis and is guiding the development of potential treatments.”
BackgroundSelf-citationGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 1×
“…fibrillar amyloid burden (but not yet soluble Ab oligomers) by PET scanning, initially with the thioflavin T derivative, Pittsburgh compound B (Klunk et al, 2004); and (iii) the ability to analyze APP metabolism in healthy and diseased humans by quantifying heavy isotope-labeled Ab peptides…”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 2×
“This category includes SORL1, BIN1, and PICALM (Rogaeva et al, 2007; Lambert et al, 2013; Zhao et al, 2015).”
BackgroundSelf-citationCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Early APP mouse models (e.g. Games et al, 1995; Hsiao et al, 1996) suffered from reliance on high transgene expression to drive plaque deposition and from a lack of tangle cytopathology and neuronal death.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Self-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 3×
“The upregulation of TREM2 in a subset of microglia in amyloid plaques of hAPP tg mice (e.g., Guerreiro et al, 2013) suggests that the known function of TREM2 in phagocytosis is compromised during plaque development.”
BackgroundSelf-citationThe molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“…in presenilins 1 and 2 alter APP proteolytic processing in a way that elevates the relative levels of the Ab42 or Ab43 peptides has long been known (Scheuner et al, 1996; NB: Those mutations in APP that lie within the Ab sequence increase the self-aggregation of the resultant peptides, not their…”
BackgroundSelf-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“Whereas the recently described loci are usually much weaker in effect (Lambert et al, 2013) or much rarer (Guerreiro et al, 2013; Jonsson et al, 2013) than ApoE4, they have helped delineate additional biological processes in AD pathogenesis.”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The amyloid (or Ab) hypothesis (Beyreuther & Masters, 1991; Hardy & Allsop, 1991; Selkoe, 1991; Hardy & Higgins, 1992) has become the dominant model of AD pathogenesis and is guiding the development of potential treatments.”
BackgroundSelf-citationAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“Early APP mouse models (e.g. Games et al, 1995; Hsiao et al, 1996) suffered from reliance on high transgene expression to drive plaque deposition and from a lack of tangle cytopathology and neuronal death.”
BackgroundVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · cited 1×
“If this time course is generally similar to that of “sporadic” AD, and the AIBL study (Villemagne et al, 2013) suggests that it is, then Ab deposition may begin up to two decades or more before clinically noticeable cognitive decline.”
ResultGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“…B (Klunk et al, 2004); and (iii) the ability to analyze APP metabolism in healthy and diseased humans by quantifying heavy isotope-labeled Ab peptides by mass spectrometry in fresh CSF collected continuously through a lumbar intrathecal catheter (Bateman et al, 2006; Mawuenyega et al, 2010).”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Solanezumab: a probable signal in mild AD Since active and passive immunotherapy to lower amyloid was first conceptualized (Schenk et al, 1999; Bard et al, 2000), antibody trials have taken the lead among putative disease-modifying therapeutics for AD.”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“The ABCA7 lipid transporter has also been identified as a genetic locus for the disease (Hollingworth et al, 2011), and loss-of-function mutations increase AD risk about threefold (Steinberg et al, 2015).”
BackgroundSelf-citationThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“As others have pointed out (Small & Duff, 2008; De Strooper & Karran, 2016) and we concur, after disease initiation, the complexity of the downstream pathogenic processes increases.”
BackgroundAmyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · cited 1×
“The discovery that Ab is normally secreted by cells throughout life (Haass et al, 1992) led to widespread compound screening on cultured cells, and most Ab-lowering “hits” that emerged inhibited c-secretase.”
BackgroundSelf-citationWolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,916 · cited 1×
“A key mechanistic explanation was the discovery that the presenilin genes encode the active site of the intramembrane-cleaving c-secretase enzyme (De Strooper et al, 1998; Wolfe et al, 1999).”
BackgroundSelf-citationReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 2×
“A key mechanistic explanation was the discovery that the presenilin genes encode the active site of the intramembrane-cleaving c-secretase enzyme (De Strooper et al, 1998; Wolfe et al, 1999).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 3×
“Even more remarkable has been the identification of an APP missense mutation (A673T) at the second amino acid of the Ab region that results in a lifelong decrease in APP cleavage by b-secretase (Jonsson et al, 2012).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 2×
“Accordingly, these 3 genes undergo increased expression during plaque development (Griciuc et al 2013, Wang et al, 2015; Matarin et al, 2015) and CSF TREM2 levels go up as plaque load increases, suggesting it may be a useful biomarker (Suárez-Calvet et al, 2016).”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“These brains were selected to have similar plaque densities, but the oligomer-specific ELISA revealed that the non-demented plaque-rich subjects had much lower oligomer-to-plaque ratios than the mildly demented plaque-rich patients (Esparza et al, 2013).”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“TREM2 is emerging as a key molecular determinant of the CNS response to Ab accumulation (Forabosco et al, 2013; Zhang et al, 2013; Matarin et al, 2015).”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“Crossing FAD-mutant APP mice with mutant MAPT (tau) transgenic (tg) mice succeeded in augmenting tau pathology and suggested that tangle-like changes occur downstream of Ab accumulation, but this involved transgene overexpression and multiple AD mutations (Lewis et al, 2001).”
BackgroundSelf-citationLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Self-citationSingle App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 1×
“Recently, mice with gradual Ab plaque accrual have been developed by the judicious use of selective knockin of human mutations into endogenous mouse APP without overexpression (Saito et al, 2014).”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 1×
“…longer at the forefront but not forgotten AD immunotherapy in man began with an active vaccine trial (using AN-1792, a synthetic Ab1–42 peptide) that was terminated after 2–3 doses due to the occurrence of a T-cell mediated meningeal inflammation in 6% of the Phase 2 patients (Gilman et al, 2005).”
BackgroundRovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · cited 1×
“Conversely, those rare individuals who have the APP gene micro-duplicated but not the rest of the chromosome do not have Down’s syndrome but get AD, typically in their mid-50s (Rovelet-Lecrux et al, 2006).”
BackgroundHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 3×
“A detailed quantitative study of Ab homeostasis using in vivo microdialysis in hAPP × hApoE crossed mice has shown that Ab clearance (but not Ab production) is decreased by ApoE4 > E3 > E2, closely paralleling the degree of Ab deposition in such mice (Castellano et al, 2011).”
BackgroundMethodA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · cited 1×
“The only such compound to reach Phase 3 testing was semagacestat, but the trial was terminated after ~12 months of dosing due to adverse events (Doody et al, 2013).”
BackgroundA three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · cited 1×
“…biopsies of FAD subjects have been used to show first Ab accumulation and then tau alteration in the absence of overexpression (Shi et al, 2012; Choi et al, 2014; Muratore et al, 2014; Moore et al, 2015) suggesting that the lack of tangle formation in early mouse models was related to the…”
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 5×
“In accord, one of the numerous risk genes for late-onset AD is PICALM, and AD-promoting alleles or knockdown of this gene has been shown to decrease Ab clearance across the brain endothelium (Zhao et al 2015).”
BackgroundInfluentialApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · cited 2×
“How ApoE4 promotes AD: chronically decreased Aß clearance Humans expressing the ApoE4 protein develop more plaque and vascular b-amyloid deposits than those expressing only ApoE3 (Rebeck et al, 1993), and this has been confirmed in genetically engineered mice (Holtzman et al, 2000).”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · cited 1×
“Overall, brain imaging and CSF biomarker studies in humans suggest that the sequence of AD pathogenic steps currently measurable in vivo broadly follows the schema proposed by Jack and colleagues (Jack & Holtzman, 2013; Jack et al, 2013; Fig 3).”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“How ApoE4 promotes AD: chronically decreased Aß clearance Humans expressing the ApoE4 protein develop more plaque and vascular b-amyloid deposits than those expressing only ApoE3 (Rebeck et al, 1993), and this has been confirmed in genetically engineered mice (Holtzman et al, 2000).”
BackgroundJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876
Self-citationMa, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871 · cited 1×
“As a potentially related effect on Ab homeostasis, the three ApoE isoforms have also been shown to bind Ab differentially and modulate its fibrillogenesis (Ma et al, 1994; Wisniewski et al, 1994; Evans et al, 1995).”
BackgroundKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“The latter findings fit nicely with evidence in hAPP tg mice that plaques in situ have a penumbra of soluble Ab oligomers in which synaptic density is low; synapse number rises toward normal the farther one measures from the edge of the plaque core (Koffie et al, 2009).”
BackgroundApolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829 · cited 1×
“Other potential mechanisms have been suggested, including an adverse effect of ApoE4 on the processing of tau in neurons (Andrews-Zwilling et al, 2010; Huang & Mahley, 2014).”
BackgroundBrown, P., Gibbs, C. J., Rodgers‐Johnson, P., Asher, D. M., Sulima, M. P., Bacote, A., Goldfarb, L. G., & Gajdusek, D. C. (1994) · Annals of Neurology · doi:10.1002/ana.410350504 · Cited by 817 · cited 1×
“Attempts by Gadjusek and colleagues more than 30 years ago to transmit AD to lower primates by inoculation of AD brain extracts were deemed unsuccessful (Brown et al, 1994).”
BackgroundTau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807 · cited 1×
“In both cellular and mouse models, extensive data now suggest that the neurotoxicity of Ab is in considerable part dependent on expression of human tau (Rapoport et al, 2002; Jin et al, 2011; Roberson et al, 2011).”
BackgroundTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 2×
“However, the biology of TREM2, a Type 1 single-transmembrane receptor which is principally but not exclusively expressed in microglia and undergoes ADAM/ c-secretase processing (Wunderlich et al, 2013; Kleinberger et al, 2014), is incompletely understood [reviewed in (Lue et al, 2015)].”
BackgroundSelf-citationHypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783 · cited 1×
“…and other components of cholesterol/sterol metabolism A role for cholesterol in AD has long been suspected, based on the genetic implication of ApoE in the disease as well as the contrasting effects of cholesterol loading or depletion on amyloid pathology in APP tg mice (Refolo et al, 2000, 2001).”
BackgroundThe A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760 · cited 1×
“Importantly, the first prevention trial in largely pre-symptomatic humans at risk of lateonset AD (ages 65–85) based on abnormal PET amyloid scans is now underway in > 60 centers in the United States, Canada and Australia [A4study.org] (Sperling et al, 2014).”
BackgroundMaruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“…discovery of many new substrates of b-secretase, including some that are critical for signaling events in both the immature and mature nervous system (Willem et al, 2006; Hemming et al, 2009; Kuhn et al, 2012), raises the possibility of significant adverse events appearing over time in such trials.”
BackgroundEarly Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675 · cited 1×
“The recent development of imaging agents for tangles (Chien et al, 2013; Liang et al, 2014) will help define the time course of accrual of the two major lesions, although tangles are somewhat non-specific in that they occur increasingly with “normal” aging and in several neurodegenerative processes…”
BackgroundAndersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“The recent development of imaging agents for tangles (Chien et al, 2013; Liang et al, 2014) will help define the time course of accrual of the two major lesions, although tangles are somewhat non-specific in that they occur increasingly with “normal” aging and in several neurodegenerative processes…”
BackgroundJones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606 · cited 3×
“Progressive cleavages of the APP transmembrane domain by the Presenilin/c-secretase complex. innate immune system; and endosomal vesicle recycling (Jones et al, 2010).”
BackgroundInfluentialSelf-citationHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · cited 1×
“…B (Klunk et al, 2004); and (iii) the ability to analyze APP metabolism in healthy and diseased humans by quantifying heavy isotope-labeled Ab peptides by mass spectrometry in fresh CSF collected continuously through a lumbar intrathecal catheter (Bateman et al, 2006; Mawuenyega et al, 2010).”
BackgroundLemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 2×
“Inherited mutations in APP and presenilin (i.e., in the substrate and the protease for Ab generation) cause early-onset Ab deposition (Lemere et al, 1996a,b; Bateman et al, 2012) followed by accumulation of tangles/neurites containing filaments of wild-type tau, so amyloid can clearly precede…”
BackgroundResultSelf-citationLinking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 1×
“As others have pointed out (Small & Duff, 2008; De Strooper & Karran, 2016) and we concur, after disease initiation, the complexity of the downstream pathogenic processes increases.”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 521
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A. S., et al. (2015) · Nature · doi:10.1038/nature15369 · Cited by 518 · cited 1×
“…patients dying between ages 36 and 51 of iatrogenic Creutzfeld–Jakob disease after childhood treatment for short stature with prion-contaminated cadaveric pituitary extracts were reported to also have substantial Ab-immunoreactive plaques and microvessels in their brains (Jaunmuktane et al, 2015).”
BackgroundBertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 4×
“Biochem Biophys Res Commun 120: 885 – 890 Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta.”
BackgroundInfluentialAn atomic structure of human γ-secretase
Bai, X.-C., Yan, C., Yang, G., Lu, P., Ma, D., Sun, L., Zhou, R., Scheres, S. H. W., & Shi, Y. (2015) · Nature · doi:10.1038/nature14892 · Cited by 498 · cited 1×
“…catalytic mechanism of this first-in-class intramembrane aspartyl protease is incompletely understood, although substantial progress should ensue from biochemical studies that take advantage of the atomic structure of the whole c-secretase complex that has recently been solved (Bai et al, 2015).”
BackgroundTakami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · cited 1×
“Subsequent studies have begun to illuminate how presenilin mediates intramembrane proteolysis (Qi-Takahara et al, 2005; Takami et al, 2009; Chavez-Gutierrez et al, 2012; Okochi et al, 2013; Fernandez et al, 2014): an initial endopeptidase cleavage of APP near the transmembrane/cytoplasmic interface…”
BackgroundResolving controversies on the path to Alzheimer's therapeutics
Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494 · cited 1×
“Precisely why this idea has been so controversial is not clear (Selkoe, 2011), but the steady accrual of data from many preclinical and clinical studies has increasingly supported it.”
BackgroundSelf-citationLemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1146 · Cited by 487 · cited 2×
“Inherited mutations in APP and presenilin (i.e., in the substrate and the protease for Ab generation) cause early-onset Ab deposition (Lemere et al, 1996a,b; Bateman et al, 2012) followed by accumulation of tangles/neurites containing filaments of wild-type tau, so amyloid can clearly precede…”
BackgroundResultSelf-citationShen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 2×
“One group has emphasized that the aforementioned mechanism represents a loss of function of presenilin and have proposed that the neural phenotype of AD patients is fundamentally due to a loss of presenilin function, independent of effects on Ab production (Shen & Kelleher, 2007; Xia et al, 2015).”
BackgroundMass spectrometry of purified amyloid beta protein in Alzheimer's disease.
Mori, H., Takio, K., Ogawara, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 483 · cited 1×
“One well-studied variant that is highly amyloidogenic (Nussbaum et al, 2012) is the “p3E” Ab peptide that is truncated over time of Asp1 and Ala2 and then cyclized at Glu3 (Mori et al, 1992).”
BackgroundSelf-citationAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · cited 1×
“Further, during the period of amyloid deposition, the Ab42 monomer declines in CSF in a manner that suggests it becomes bound to developing plaques (Blennow et al, 2015).”
BackgroundImmune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 459 · cited 1×
“For example, the early observation of multiple elements of the classical complement cascade in and around neuritic plaques (McGeer et al, 1989) was prescient.”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 1×
“DeMattos et al (2012) have shown in hAPP transgenic mice that this variant accumulates rather late and in small amounts, but targeting it with a specific antibody promotes a kind of “bystander clearance” by microglia of also earlier deposited Ab species, making p3E an attractive target for Ab…”
BackgroundAcceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
(1994) · PubMed Central · Cited by 441
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427 · cited 1×
“One well-studied variant that is highly amyloidogenic (Nussbaum et al, 2012) is the “p3E” Ab peptide that is truncated over time of Asp1 and Ala2 and then cyclized at Glu3 (Mori et al, 1992).”
BackgroundAβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415 · cited 1×
“Ab42, Ab43, and longer Ab peptides are highly self-aggregating, whereas Ab40 may actually be antiamyloidogenic (Kim et al, 2007).”
BackgroundMolecular mapping of alzheimer‐type dementia in Down's syndrome
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C., & Butler, A. C. (1998) · Annals of Neurology · doi:10.1002/ana.410430316 · Cited by 414 · cited 2×
“Levels of these extended monomers rise dramatically when b-secretase inhibitors are applied to the cells, indicating that they arise from an alternative protease(s) which EMBO Molecular Medicine Vol 8 | No 6 | 2016 ª 2016 The Authors cleaves APP upstream of the Met-Asp bond.”
BackgroundCentral role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4025 · Cited by 410 · cited 3×
“In accord, one of the numerous risk genes for late-onset AD is PICALM, and AD-promoting alleles or knockdown of this gene has been shown to decrease Ab clearance across the brain endothelium (Zhao et al 2015).”
Backgroundη-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398
Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., Kametani, F., Maeda, M., Saido, T. C., Wang, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1575-04.2005 · Cited by 391 · cited 1×
“Subsequent studies have begun to illuminate how presenilin mediates intramembrane proteolysis (Qi-Takahara et al, 2005; Takami et al, 2009; Chavez-Gutierrez et al, 2012; Okochi et al, 2013; Fernandez et al, 2014): an initial endopeptidase cleavage of APP near the transmembrane/cytoplasmic interface…”
BackgroundMuratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379 · cited 1×
“…FAD subjects have been used to show first Ab accumulation and then tau alteration in the absence of overexpression (Shi et al, 2012; Choi et al, 2014; Muratore et al, 2014; Moore et al, 2015) suggesting that the lack of tangle formation in early mouse models was related to the absence of human tau.”
BackgroundSelf-citationCoric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · cited 1×
“Another agent, avagacestat, had a better therapeutic index but still not good enough to avoid certain side effects and be advanced to Phase 3 trials (Coric et al, 2012).”
BackgroundClinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 373
Evans, K. C., Berger, E. P., Cho, C. G., Weisgraber, K. H., & Lansbury, P. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.763 · Cited by 333 · cited 1×
“As a potentially related effect on Ab homeostasis, the three ApoE isoforms have also been shown to bind Ab differentially and modulate its fibrillogenesis (Ma et al, 1994; Wisniewski et al, 1994; Evans et al, 1995).”
BackgroundAndrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326 · cited 1×
“Other potential mechanisms have been suggested, including an adverse effect of ApoE4 on the processing of tau in neurons (Andrews-Zwilling et al, 2010; Huang & Mahley, 2014).”
BackgroundLoss-of-function variants in ABCA7 confer risk of Alzheimer's disease
DemGene, Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O. T., Gudjonsson, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3246 · Cited by 324 · cited 1×
“The ABCA7 lipid transporter has also been identified as a genetic locus for the disease (Hollingworth et al, 2011), and loss-of-function mutations increase AD risk about threefold (Steinberg et al, 2015).”
BackgroundJiang, T., Tan, L., Zhu, X.-C., Zhang, Q.-Q., Cao, L., Tan, M.-S., Gu, L.-Z., Wang, H.-F., Ding, Z.-Z., Zhang, Y.-D., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.164 · Cited by 320 · cited 1×
“Conversely, TREM2 overexpression in hAPP tg mice decreased amyloid plaque burden, neuroinflammation, synapse loss, and spatial memory deficits (Jiang et al, 2014).”
BackgroundA Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome
Shi, Y., Kirwan, P., Smith, J., MacLean, G., Orkin, S. H., & Livesey, F. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003771 · Cited by 310 · cited 1×
“…cultured from skin biopsies of FAD subjects have been used to show first Ab accumulation and then tau alteration in the absence of overexpression (Shi et al, 2012; Choi et al, 2014; Muratore et al, 2014; Moore et al, 2015) suggesting that the lack of tangle formation in early mouse models was…”
BackgroundAmyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls
Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2013) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 306 · cited 1×
“These brains were selected to have similar plaque densities, but the oligomer-specific ELISA revealed that the non-demented plaque-rich subjects had much lower oligomer-to-plaque ratios than the mildly demented plaque-rich patients (Esparza et al, 2013).”
BackgroundAltered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302 · cited 1×
“Deleting one TREM2 allele in hAPP tg mice significantly decreased the number of microglia associated with Ab deposits (Ulrich et al, 2014).”
BackgroundSecretome protein enrichment identifies physiological BACE1 protease substrates in neurons
Kuhn, P., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.173 · Cited by 301 · cited 1×
“…discovery of many new substrates of b-secretase, including some that are critical for signaling events in both the immature and mature nervous system (Willem et al, 2006; Hemming et al, 2009; Kuhn et al, 2012), raises the possibility of significant adverse events appearing over time in such trials.”
BackgroundWunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296 · cited 1×
“However, the biology of TREM2, a Type 1 single-transmembrane receptor which is principally but not exclusively expressed in microglia and undergoes ADAM/ c-secretase processing (Wunderlich et al, 2013; Kleinberger et al, 2014), is incompletely understood [reviewed in (Lue et al, 2015)].”
BackgroundMatarin, M., Salih, D. A., Yasvoina, M., Cummings, D. M., Guelfi, S., Liu, W., Nahaboo Solim, M. A., Moens, T. G., Paublete, R. M., Ali, S. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.041 · Cited by 290 · cited 2×
“Accordingly, these 3 genes undergo increased expression during plaque development (Griciuc et al 2013, Wang et al, 2015; Matarin et al, 2015) and CSF TREM2 levels go up as plaque load increases, suggesting it may be a useful biomarker (Suárez-Calvet et al, 2016).”
BackgroundSelf-citationPotent amyloidogenicity and pathogenicity of Aβ43
Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., Matsuba, Y., Yamada, K., Nilsson, P., Takano, J., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2858 · Cited by 280 · cited 2×
“They have studied presenilin-1 mutations that generally lower Ab and hardly raise relative Ab42 levels, but this work may overlook an elevation of the Ab43 and other longer species, which are highly amyloidogenic (Saito et al, 2011).”
BackgroundLessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Karran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275 · cited 1×
“Several of these trials, however, were misdesigned in terms of patient selection, choice of agent, target engagement, and/or dose, or they had to be halted because of side effects that may not have been target-related (De Strooper, 2014; Karran & Hardy, 2014).”
BackgroundSelf-citationIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · cited 1×
“…infusions to label all newly synthesized proteins, including APP, in pre-symptomatic subjects with presenilin mutations and their non-carrier siblings confirmed the extensive data in cultures and mouse models that these AD-causing mutations increase relative Ab42 production (Potter et al, 2013).”
BackgroundPresenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer’s Disease
Xia, D., Watanabe, H., Wu, B., Lee, S. H., Li, Y., Tsvetkov, E., Bolshakov, V. Y., Shen, J., & Kelleher, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.010 · Cited by 228 · cited 1×
“SORL1 had previously been shown to be directly involved in the processing of APP (Andersen et al, 2005), and work in human stem cell-derived neurons carrying the SORL1 risk haplotype confirmed this association (Young et al, 2015).”
ResultVigo-Pelfrey, C., Seubert, P. P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B., Lieberburg, I., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · cited 14×
“The problem has been substantially lessened by three developments: (i) robust assays to quantify soluble Ab monomers and tau in CSF (Vigo-Pelfrey et al, 1995); (ii) imaging fibrillar amyloid burden (but not yet soluble Ab oligomers) by PET scanning, initially with the thioflavin T derivative, Pittsburgh compound B (Kl…”
BackgroundInfluentialBeyreuther, K., & Masters, C. L. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00667.x · Cited by 221 · cited 1×
“The amyloid (or Ab) hypothesis (Beyreuther & Masters, 1991; Hardy & Allsop, 1991; Selkoe, 1991; Hardy & Higgins, 1992) has become the dominant model of AD pathogenesis and is guiding the development of potential treatments.”
BackgroundHong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213 · cited 1×
“We have hypothesized that plaques can sequester soluble oligomers until they slowly reach a physical limit, after which excess oligomers can diffuse onto surrounding synaptic membranes and other hydrophobic cell surfaces (Hong et al, 2014).”
Self-citationKim, W. S., Li, H., Ruberu, K., Chan, S., Elliott, D. A., Low, J. K., Cheng, D., Karl, T., & Garner, B. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4165-12.2013 · Cited by 208 · cited 1×
“Crossing ABCA7 knockout mice to mutant hAPP mice caused a doubling of insoluble Ab levels and amyloid plaques without changing APP processing, suggesting that like ApoE, ABCA7 is involved in Ab clearance (Kim et al, 2013).”
BackgroundMaloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 197
Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
Hemming, M. L., Elias, J. E., Gygi, S. P., & Selkoe, D. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008477 · Cited by 194 · cited 1×
“…discovery of many new substrates of b-secretase, including some that are critical for signaling events in both the immature and mature nervous system (Willem et al, 2006; Hemming et al, 2009; Kuhn et al, 2012), raises the possibility of significant adverse events appearing over time in such trials.”
BackgroundSelf-citationYoung, J. E., Boulanger-Weill, J., Williams, D. A., Woodruff, G., Buen, F., Revilla, A. C., Herrera, C., Israel, M. A., Yuan, S. H., Edland, S. D., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.004 · Cited by 188 · cited 1×
“SORL1 had previously been shown to be directly involved in the processing of APP (Andersen et al, 2005), and work in human stem cell-derived neurons carrying the SORL1 risk haplotype confirmed this association (Young et al, 2015).”
ResultVery long term studies of the seeding of β-amyloidosis in primates
Ridley, R. M., Baker, H. F., Windle, C. P., & Cummings, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0385-2 · Cited by 186
Insights into TREM2 biology by network analysis of human brain gene expression data
Forabosco, P., Ramasamy, A., Trabzuni, D., Walker, R., Smith, C., Bras, J., Levine, A. P., Hardy, J., Pocock, J. M., Guerreiro, R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.001 · Cited by 180 · cited 1×
“TREM2 is emerging as a key molecular determinant of the CNS response to Ab accumulation (Forabosco et al, 2013; Zhang et al, 2013; Matarin et al, 2015).”
BackgroundSelf-citationAPP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.
Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179 · cited 1×
“…FAD subjects have been used to show first Ab accumulation and then tau alteration in the absence of overexpression (Shi et al, 2012; Choi et al, 2014; Muratore et al, 2014; Moore et al, 2015) suggesting that the lack of tangle formation in early mouse models was related to the absence of human tau.”
BackgroundSelf-citationIrwin, D. J., Abrams, J. Y., Schonberger, L. B., Leschek, E. W., Mills, J. L., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1933 · Cited by 168 · cited 1×
“No tangles or AD-type neuritic/microglia-rich plaques were described, so this was not transmission of AD per se, consistent with an earlier negative study (Irwin et al, 2013).”
ResultSerrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159
Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
Szaruga, M., Veugelen, S., Benurwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., Ryan, N. S., Lashley, T., Fox, N. C., Murayama, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150892 · Cited by 155 · cited 1×
“…directly in presenilin-mutant AD brain tissue showed that all presenilin mutations studied decreased this carboxypeptidase-like activity, and assays in a few “sporadic” AD brains suggested that a similar decrease in processivity might occur in some non-presenilin-mutant cases (Szaruga et al, 2015).”
BackgroundFeldman, R. G., Chandler, K. A., Levy, L. L., & Glaser, G. H. (1963) · Neurology · doi:10.1212/wnl.13.10.811 · Cited by 152
Holtzman, D. M., Mandelkow, E., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011585 · Cited by 151
Self-citationBenilova, I., Gallardo, R., Ungureanu, A.-A., Castillo Cano, V., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J., & De Strooper, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599027 · Cited by 145 · cited 1×
“Moreover, this benefit may be compounded, because the ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 6 | 2016 mutant Ab peptide that is generated has altered aggregation properties (Benilova et al, 2014; Maloney et al, 2014; Zheng et al, 2015).”
BackgroundFernandez, M. A., Klutkowski, J. A., Freret, T., & Wolfe, M. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.581165 · Cited by 136 · cited 1×
“…how presenilin mediates intramembrane proteolysis (Qi-Takahara et al, 2005; Takami et al, 2009; Chavez-Gutierrez et al, 2012; Okochi et al, 2013; Fernandez et al, 2014): an initial endopeptidase cleavage of APP near the transmembrane/cytoplasmic interface of APP (the e-cleavage) is followed by…”
BackgroundOkochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123 · cited 1×
“…begun to illuminate how presenilin mediates intramembrane proteolysis (Qi-Takahara et al, 2005; Takami et al, 2009; Chavez-Gutierrez et al, 2012; Okochi et al, 2013; Fernandez et al, 2014): an initial endopeptidase cleavage of APP near the transmembrane/cytoplasmic interface of APP (the…”
BackgroundKanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., & Iwatsubo, T. (2014) · Nature Communications · doi:10.1038/ncomms4386 · Cited by 111 · cited 1×
“Likewise, PICALM appears to be involved directly in endosomal APP processing (Kanatsu et al, 2014).”
BackgroundBlockage of CR1 prevents activation of rodent microglia
Crehan, H., Hardy, J., & Pocock, J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.02.003 · Cited by 98 · cited 1×
“Blockade of CR1 inhibits microglial activation and potentiates microglial phagocytosis (Crehan et al, 2013).”
BackgroundSelf-citationWelzel, A. T., Maggio, J. E., Shankar, G. M., Walker, D. E., Ostaszewski, B. L., Li, S., Klyubin, I., Rowan, M. J., Seubert, P., Walsh, D. M., et al. (2014) · Biochemistry · doi:10.1021/bi5003053 · Cited by 98 · cited 2×
“One example is the detection in certain cell lines expressing pathogenic mutant APP, of Ab monomers and dimers as well as N-terminally extended Ab monomers that begin some ~35–40 resides before the Asp1 of Ab (Welzel et al, 2014).”
BackgroundSelf-citationAyutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A. S., Friesenhahn, M., Ward, M., Aguirre, C., Acosta-Baena, N., Madrigal, L., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08927 · Cited by 78
Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population
Kero, M., Paetau, A., Polvikoski, T., Tanskanen, M., Sulkava, R., Jansson, L., Myllykangas, L., & Tienari, P. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.017 · Cited by 72 · cited 1×
“A673T carriers have a lower risk of clinical AD and even of age-related cognitive decline without clinical AD (Jonsson et al, 2012), and they may not show plaque deposition at age 100 (Kero et al, 2013).”
BackgroundKretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P., Kremmer, E., Giese, A., Lichtenthaler, S. F., Haass, C., Arzberger, T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505952 · Cited by 72 · cited 1×
“…as partial loss of function from a genetics perspective, pinpointing the function of presenilin as an aspartyl endopeptidase allows one instead to speak in biochemical terms of a functional shift of the principal proteolytic cleavages to more C-terminal bonds in the substrate (Kretner et al, 2016).”
BackgroundLue, L.-F., Schmitz, C., & Walker, D. G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.050 · Cited by 63 · cited 1×
“However, the biology of TREM2, a Type 1 single-transmembrane receptor which is principally but not exclusively expressed in microglia and undergoes ADAM/ c-secretase processing (Wunderlich et al, 2013; Kleinberger et al, 2014), is incompletely understood [reviewed in (Lue et al, 2015)].”
BackgroundZheng, X., Liu, D., Roychaudhuri, R., Teplow, D. B., & Bowers, M. T. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00171 · Cited by 62 · cited 1×
“Moreover, this benefit may be compounded, because the ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 6 | 2016 mutant Ab peptide that is generated has altered aggregation properties (Benilova et al, 2014; Maloney et al, 2014; Zheng et al, 2015).”
BackgroundLiang, S. H., Yokell, D. L., Normandin, M. D., Rice, P. A., Jackson, R. N., Shoup, T. M., Brady, T. J., Fakhri, G. E., Collier, T. L., & Vasdev, N. (2014) · Molecular Imaging · doi:10.2310/7290.2014.00025 · Cited by 40 · cited 1×
“The recent development of imaging agents for tangles (Chien et al, 2013; Liang et al, 2014) will help define the time course of accrual of the two major lesions, although tangles are somewhat non-specific in that they occur increasingly with “normal” aging and in several neurodegenerative processes…”
BackgroundSevigny, J., Chiao, P., Williams, L., Chen, T., Ling, Y., O'Gorman, J., Hock, C., Nitsch, R. M., & Sandrock, A. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.367 · Cited by 40 · cited 1×
“The 3 and 10 mg dose reduced PET amyloid levels at 6 months and more so at 12 months, with the 10 mg dose causing a decline to near the level required for trial entry (Sevigny et al, 2015).”
The Biology of Alzheimer Disease
Landau, S. M., & Doraiswamy, P. M. (2012) · JAMA · doi:10.1001/jama.308.18.1925 · Cited by 30 · cited 1×
“Space precludes a full examination here of the enormous literature on Ab since that review; a monograph on AD pathobiology contains many details (Selkoe et al, 2012).”
BackgroundGermany’s renewable revolution awaits energy forecast
Schiermeier, Q. (2016) · Nature · doi:10.1038/535212a · Cited by 29
The biology of Alzheimer disease
Selkoe, D. J., Mandelkow�, E., & Holtzman, D. M. (2012) · Cold Spring Harbor Laboratory eBooks · Cited by 21
Self-citation
Research works printed but not linked: 3
- Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, Clayton D, Mortensen D, Ho C, Paul R (2014) paper presented at the Alzheimer's Association International Conference (AAIC), Copenhagen, Denmark, 16 July 2014
- Mann DMA, Yuonis N, Jones D, Stoddart DW (1992) The time course of pathological events in Down's Syndrome with particular reference to the involvement of microglial cells and deposits of b/A4. Neurodegeneration 1: 201–215
- Sevigny J, Chiao P, Williams L, Miao X, O'Gorman J (2015) Randomized, double‐blind Phase 1B study of BIIB037, an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease. Neurogener Dis 15(Suppl 1): 311
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“This hypothesis has been the leading model of AD pathogenesis since it was first proposed, although portions have been revised or supplemented over time (Musiek and Holtzman, 2015; Selkoe and Hardy, 2016).”
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
“It is important to note, however, that many of these studies have been complicated by concern over target engagement and patient selection [72]: not only did a proportion of individuals recruited for some of these trials not have evidence for AD pathology [28], but most studies have targeted patients with laterstage A…”
BackgroundResultSelf-citationOxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
“early 1990s [31–34] has become a dominant model for AD pathogenesis [35], although still controversial [36,37].”
BackgroundGut microbiome alterations in Alzheimer’s disease
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13601-y · Cited by 2,137
Metadata
- Authors
- Selkoe, D. J., & Hardy, J.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Hardy, John
- Venue
- EMBO Molecular Medicine
- Published
- 2016-03-29
- Volume
- 8
- Issue
- 6
- Pages
- 595-608
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC4888851
- OpenAlex
- W2329336071
- Cited by
- 6,164
- References
- 137
- Citations by year
- 2026: 553 · 2025: 637 · 2024: 656 · 2023: 658 · 2022: 679 · 2021: 734 · 2020: 728 · 2019: 533 · 2018: 500 · 2017: 388 · 2016: 92
- FWCI
- 59.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Aging (AG06173, AG015379)
- MRC
- ARUK
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid-beta 42, amyloid precursor protein, presenilin, gamma-secretase, Down syndrome, APOE ε4, amyloid-beta oligomers, tau hyperphosphorylation, amyloid PET, cerebrospinal fluid biomarkers, anti-amyloid antibodies, solanezumab, crenezumab, aducanumab, amyloid clearance, neurofibrillary tangles, synaptic dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Rats, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.